Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

p16 mutations/deletions are not frequent events in prostate cancer.

British journal of cancer - 1 Jul 1996

Tamimi Y, Bringuier P P, Smit F, van Bokhoven A, Debruyne F M, Schalken J A

Abstract excerpt

Cyclin-dependent kinase-4 inhibitor gene (p16INK4) has recently been mapped to chromosome 9p21. Homozygous deletions of this gene have been found at high frequency in cell lines derived from different types of tumours. These findings suggested therefore, that p16INK4 is a tumour-suppressor gene i...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Exons
Share to Carrier Proteins
Share to Base Sequence

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Deletion

Share to Molecular Sequence Data

Share to Mutation

Share to Polymerase Chain Reaction

Share to Tumor Cells, Cultured

Source

Open in PubMed Open full text

Identifiers

PMID: 8679444
DOI: 10.1038/bjc.1996.325
PMCID: PMC2074596

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-8679444-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

p16 mutations/deletions are not frequent events in prostate cancer.PMID 8679444Read ↗

Mutations of the p16 gene product are rare in prostate cancer.Semantic proximity Read ↗

Deletional, mutational, and methylation analyses of CDKN2 (p16/MTS1) in primary and metastatic prostate cancerSemantic proximity Read ↗

Lack of mutation in the cyclin-dependent kinase inhibitor, p19INK4d, in tumor-derived cell lines and primary tumors.Semantic proximity Read ↗

Decreased expression of the p16/MTS1 gene without mutation is frequent in human urinary bladder carcinomas.Semantic proximity Read ↗

p16 (CDKN2/cyclin-dependent kinase-4 inhibitor/multiple tumor suppressor-1) gene is not altered in uterine cervical carcinomas or cell lines.Semantic proximity Read ↗

Comparative mutational analysis of DPC4 (Smad4) in prostatic and colorectal carcinomas.Semantic proximity Read ↗

Mutation analysis of the BRG1 gene in prostate cancer clinical samples.Semantic proximity Read ↗

Infrequent somatic mutations of the p16 and p15 genes in human bladder cancer: p16 mutations occur only in low-grade and superficial bladder cancers.Semantic proximity Read ↗

Homozygous deletions but no sequence mutations in coding regions of p15 or p16 in human primary bladder tumors.Semantic proximity Read ↗

Inactivation of the p16INK4A gene by methylation is not a frequent event in sporadic ovarian carcinoma.Semantic proximity Read ↗

Analysis of cyclin-dependent kinase inhibitor expression and methylation patterns in human prostate cancersSemantic proximity Read ↗

KLF6 and TP53 mutations are a rare event in prostate cancer: distinguishing between Taq polymerase artifacts and true mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.